Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01371916
Other study ID # xijing004
Secondary ID
Status Completed
Phase N/A
First received June 8, 2011
Last updated August 18, 2014
Start date September 2010
Est. completion date January 2014

Study information

Verified date August 2014
Source Xijing Hospital
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Observational

Clinical Trial Summary

Early and reliable diagnosis of tuberculous meningitis (TBM) still poses a great challenge. One of the underlying difficulties is due to the fact that tubercle bacilli are mainly not present in the cerebrospinal fluid (CSF) but in the phagocytotic macrophages. The present study was designed to demonstrate early secretory antigenic target 6 (ESAT-6), a mycobacterium-specific antigens, in the macrophages in infected CSF samples and compare the efficiency of this antigen in the laboratory diagnosis of TBM.


Description:

Tuberculosis is a disease that carries a global health burden, and tuberculous meningitis (TBM) is one of the most serious clinical manifestations of extrapulmonary tuberculosis. The failure to promptly recognize and treat patients with TBM enables the disease to exact a devastating toll around the globe despite the availability of effective chemotherapy. Therefore, accurate and timely identification of infected individuals and subsequent prompt initiation of effective anti-tuberculosis chemotherapy are essential in reducing the mortality of TBM.1 However, the disease is often difficult to diagnose with certainty, especially at early stages,2 as the presenting clinical and cerebrospinal fluid (CSF) features of TBM are non-specific and have to be differentiated from a plethora of other infectious meningitides such as viral, bacterial or cryptococcal meningitis, which frequently result in diagnostic confusion. Consequently, TBM is often diagnosed when irreversible neurologic damages have already taken place and immediate anti-tuberculosis therapy is therefore recommended regardless of the results of individual tests if TBM is seriously contemplated.

The confirmation of TBM depends on the demonstration of Mycobacterium tuberculosis in the CSF by bacteriological methods. Smear acid-fast bacillus microscopy is rapid and inexpensive, but has a very low sensitivity (10-20%),3 and culture also lacks sensitivity and is time-consuming. A number of strategies have been attempted to improve the laboratory diagnosis of TBM. Nucleic acid amplification tests (NAAT) show potential roles in confirming the diagnosis of TBM, but they, too, suffer from the problem of overall low sensitivity (0.46-0.66), partly due to a low bacillary load in the CSF.4-5 Immunodiagnostic methods have also been evaluated, but the heterogeneity of immune responses in TBM patients at the different stages of the infection poses a major obstacle to the detection of mycobacterial antibodies in CSF samples.6-7 In general, patients at the chronic stages of TBM have a myriad of antibody responses to all major antigens of Mycobacterium tuberculosis, while patients at the early stages have scarcely any detectable antibody response. In addition, interpretation of mycobacterial antibodies in the CSF must take into account the contribution of antibodies from the plasma, therefore, jeopardizing the use of these antibody-based immunodiagnostic methods in the location where they are most needed.7 One approach to provide direct evidence of existing infection is the detection of the presence of specific antigens in the circulating CSF. The first generation of these tests employed non-specific antigens as exemplified by bacille Calmette-Guerin (BCG) or purified protein derivative (PPD).8-10 Genomic analysis and antigen mining of Mycobacterium tuberculosis have yielded novel, more specific antigens, such as early secretory antigenic target 6 (ESAT-6), 38-kD antigen, and Ag85 complex.11 Nevertheless, the diagnostic efficiency of this antigen-based approach is still unsatisfactory.5-6 Mycobacterium tuberculosis belongs to the group of intracellular bacteria, which replicate within resting macrophages. During the early stages of the central nervous system (CNS) infection, the tubercle bacilli in the CSF are immediately phagocytosed by the macrophages,12-13 leading to the scarcity of mycobacterial markers in the circulating CSF. Thus, no such tests have yet become available for early diagnosis of active TBM with the requisite sensitivity and specificity.

The investigators hypothesized that, in contrast to the scarcity of mycobacterial markers in the circulating CSF, macrophages in infected CSF may carry a high load of mycobacterial antigens, which could lend themselves to the development a cell-based diagnostic approach for TBM. Here, the investigators sought to develop a smear immunocytochemical method to improve the accuracy of early diagnosis of TBM by examining early secretory antigenic target 6 (ESAT-6), a mycobacterium-specific antigens, in the macrophages in CSF specimens from patients with TBM and patients with infectious meningitis other than TBM. The investigators also compared the efficiency of this cell-based approach for detecting mycobacterial antigens with microbiological and NAAT method in the laboratory diagnosis of TBM. Further, on the basis of the clinical presentations, CSF and etiological findings in this study, the investigators proposed novel diagnostic criteria for TBM.


Recruitment information / eligibility

Status Completed
Enrollment 316
Est. completion date January 2014
Est. primary completion date November 2013
Accepts healthy volunteers No
Gender Both
Age group 14 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients older than 14 years of age

- Suspected meningitis within the previous four weeks

Exclusion Criteria:

- Entertained a final diagnosis other than infectious meningitis

- Were under anti-tuberculosis therapy on admission

- Not obtained consent from either the patients or their legal surrogates

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Locations

Country Name City State
China Xijing Hospital Xi'an Shanxi

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the positive percentage of total macrophages CSF smears from all patients were prepared and stained by standard immunocytological methods to examine the presence of ESAT-6. These negative controls did not have demonstrable staining (not shown). Positive staining was defined as visualization of yellow brown granules in the cytoplasm of macrophages. Positive and negative stained cells were counted in well-distributed visual fields. 2 days No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00433719 - Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis N/A
Completed NCT02237365 - A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis Phase 2
Not yet recruiting NCT02588196 - The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Phase 4
Completed NCT03092817 - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Phase 3
Recruiting NCT03787940 - Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis N/A
Not yet recruiting NCT05917340 - Intensified Short Course Regimen for TBM in Adults Phase 3
Completed NCT01802502 - Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation Phase 2
Recruiting NCT05636254 - Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes
Recruiting NCT03898635 - Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Completed NCT05781646 - Xpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis (TBM) in Maharaj Nakorn Chiang Mai Hospital N/A
Active, not recruiting NCT03100786 - Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis Phase 3
Recruiting NCT04145258 - Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis Phase 3
Recruiting NCT05383742 - Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis Phase 2
Completed NCT03226379 - Driving Reduced AIDS-associated Meningo-encephalitis Mortality N/A
Recruiting NCT05590455 - Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis Phase 2
Recruiting NCT04308928 - Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis